NASDAQ:AGTC - Applied Genetic Technologies Stock Price, Price Target & More

Applied Genetic Technologies trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies Corp (NASDAQ:AGTC) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.04. The biotechnology company had revenue of $3.60 million for the quarter, compared to analysts' expectations of $6.41 million. Applied Genetic Technologies had a negative net margin of 65.96% and a negative return on equity of 16.00%. View Applied Genetic Technologies' Earnings History.

Applied Genetic Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, September, 12th 2018. View Earnings Estimates for Applied Genetic Technologies.

5 brokerages have issued twelve-month target prices for Applied Genetic Technologies' stock. Their forecasts range from $7.00 to $12.00. On average, they expect Applied Genetic Technologies' share price to reach $9.00 in the next year. This suggests a possible upside of 116.9% from the stock's current price. View Analyst Ratings for Applied Genetic Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Applied Genetic Technologies in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Applied Genetic Technologies include Neon Therapeutics (NTGN), MeiraGTx (MGTX), Jounce Therapeutics (JNCE), Nantkwest (NK), Allena Pharmaceuticals (ALNA), Agenus (AGEN), ADMA Biologics (ADMA), Idera Pharmaceuticals (IDRA), Krystal Biotech (KRYS), Fennec Pharmaceuticals (FENC), Compugen (CGEN), Organovo (ONVO), Pluristem Therapeutics (PSTI), Cidara Therapeutics (CDTX) and Eiger Biopharmaceuticals (EIGR).

News coverage about AGTC stock has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Applied Genetic Technologies earned a news sentiment score of 0.09 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 46.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Applied Genetic Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include Municipal Employees Retirement System of Michigan (1.33%). Company insiders that own Applied Genetic Technologies stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies.

AGTC stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Applied Genetic Technologies.

Shares of AGTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AGTC stock can currently be purchased for approximately $4.15.

Applied Genetic Technologies has a market capitalization of $75.16 million and generates $39.47 million in revenue each year. The biotechnology company earns $400,000.00 in net income (profit) each year or $0.02 on an earnings per share basis. Applied Genetic Technologies employs 72 workers across the globe.

Applied Genetic Technologies' mailing address is 14193 NW 119TH TERRACE SUITE 10, ALACHUA FL, 32615. The biotechnology company can be reached via phone at 386-462-2204.